Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

2.

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.

Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, G√ľnthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT; International AIDS Society-USA.

JAMA. 2010 Jul 21;304(3):321-33. doi: 10.1001/jama.2010.1004.

PMID:
20639566
3.

Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1.

Taiwo B, Chaplin B, Penugonda S, Meloni S, Akanmu S, Gashau W, Idoko J, Adewole I, Murphy R, Kanki P.

Curr HIV Res. 2010 Apr;8(3):194-8.

PMID:
20163340
4.

DART points the way for HIV treatment programmes.

Phillips A, van Oosterhout J.

Lancet. 2010 Jan 9;375(9709):96-8. doi: 10.1016/S0140-6736(09)62103-6. Epub 2009 Dec 8. No abstract available.

PMID:
20004465
5.

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.

DART Trial Team, Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, Kityo C, Reid A, Grosskurth H, Darbyshire JH, Ssali F, Bray D, Katabira E, Babiker AG, Gilks CF, Grosskurth H, Munderi P, Kabuye G, Nsibambi D, Kasirye R, Zalwango E, Nakazibwe M, Kikaire B, Nassuna G, Massa R, Fadhiru K, Namyalo M, Zalwango A, Generous L, Khauka P, Rutikarayo N, Nakahima W, Mugisha A, Todd J, Levin J, Muyingo S, Ruberantwari A, Kaleebu P, Yirrell D, Ndembi N, Lyagoba F, Hughes P, Aber M, Lara AM, Foster S, Amurwon J, Wakholi BN, Whitworth J, Wangati K, Amuron B, Kajungu D, Nakiyingi J, Omony W, Fadhiru K, Nsibambi D, Khauka P, Mugyenyi P, Kityo C, Ssali F, Tumukunde D, Otim T, Kabanda J, Musana H, Akao J, Kyomugisha H, Byamukama A, Sabiiti J, Komugyena J, Wavamunno P, Mukiibi S, Drasiku A, Byaruhanga R, Labeja O, Katundu P, Tugume S, Awio P, Namazzi A, Bakeinyaga GT, Katabira H, Abaine D, Tukamushaba J, Anywar W, Ojiambo W, Angweng E, Murungi S, Haguma W, Atwiine S, Kigozi J, Namale L, Mukose A, Mulindwa G, Atwiine D, Muhwezi A, Nimwesiga E, Barungi G, Takubwa J, Murungi S, Mwebesa D, Kagina G, Mulindwa M, Ahimbisibwe F, Mwesigwa P, Akuma S, Zawedde C, Nyiraguhirwa D, Tumusiime C, Bagaya L, Namara W, Kigozi J, Karungi J, Kankunda R, Enzama R, Latif A, Hakim J, Robertson V, Reid A, Chidziva E, Bulaya-Tembo R, Musoro G, Taziwa F, Chimbetete C, Chakonza L, Mawora A, Muvirimi C, Tinago G, Svovanapasis P, Simango M, Chirema O, Machingura J, Mutsai S, Phiri M, Bafana T, Chirara M, Muchabaiwa L, Muzambi M, Mutowo J, Chivhunga T, Chigwedere E, Pascoe M, Warambwa C, Zengeza E, Mapinge F, Makota S, Jamu A, Ngorima N, Chirairo H, Chitsungo S, Chimanzi J, Maweni C, Warara R, Matongo M, Mudzingwa S, Jangano M, Moyo K, Vere L, Mdege N, Machingura I, Katabira E, Ronald A, Kambungu A, Lutwama F, Mambule I, Nanfuka A, Walusimbi J, Nabankema E, Nalumenya R, Namuli T, Kulume R, Namata I, Nyachwo L, Florence A, Kusiima A, Lubwama E, Nairuba R, Oketta F, Buluma E, Waita R, Ojiambo H, Sadik F, Wanyama J, Nabongo P, Oyugi J, Sematala F, Muganzi A, Twijukye C, Byakwaga H, Ochai R, Muhweezi D, Coutinho A, Etukoit B, Gilks C, Boocock K, Puddephatt C, Grundy C, Bohannon J, Winogron D, Gibb DM, Burke A, Bray D, Babiker A, Walker AS, Wilkes H, Rauchenberger M, Sheehan S, Spencer-Drake C, Taylor K, Spyer M, Ferrier A, Naidoo B, Dunn D, Goodall R, Darbyshire JH, Peto L, Nanfuka R, Mufuka-Kapuya C, Kaleebu P, Pillay D, Robertson V, Yirrell D, Tugume S, Chirara M, Katundu P, Ndembi N, Lyagoba F, Dunn D, Goodall R, McCormick A, Lara AM, Foster S, Amurwon J, Wakholi BN, Kigozi J, Muchabaiwa L, Muzambi M, Weller I, Babiker A, Bahendeka S, Bassett M, Wapakhabulo AC, Darbyshire JH, Gazzard B, Gilks C, Grosskurth H, Hakim J, Latif A, Mapuchere C, Mugurungi O, Mugyenyi P, Burke C, Jones S, Newland C, Pearce G, Rahim S, Rooney J, Smith M, Snowden W, Steens JM, Breckenridge A, McLaren A, Hill C, Matenga J, Pozniak A, Serwadda D, Peto T, Palfreeman A, Borok M, Katabira E.

Lancet. 2010 Jan 9;375(9709):123-31. doi: 10.1016/S0140-6736(09)62067-5. Epub 2009 Dec 8.

6.

Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.

Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N.

Antivir Ther. 2009;14(3):339-47.

PMID:
19474468
7.

Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda.

Reynolds SJ, Nakigozi G, Newell K, Ndyanabo A, Galiwongo R, Boaz I, Quinn TC, Gray R, Wawer M, Serwadda D.

AIDS. 2009 Mar 27;23(6):697-700. doi: 10.1097/QAD.0b013e3283262a78.

8.

CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy.

Moore DM, Awor A, Downing R, Kaplan J, Montaner JS, Hancock J, Were W, Mermin J.

J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):477-84. doi: 10.1097/QAI.0b013e318186eb18.

PMID:
18989232
9.

Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa.

Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD.

AIDS. 2008 Oct 1;22(15):1971-7. doi: 10.1097/QAD.0b013e32830e4cd8.

PMID:
18784460
10.
11.

Running with scissors: using antiretroviral therapy without monitoring viral load.

Smith DM, Schooley RT.

Clin Infect Dis. 2008 May 15;46(10):1598-600. doi: 10.1086/587110. No abstract available.

12.

A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy.

Hornberger J, Holodniy M, Robertus K, Winnike M, Gibson E, Verhulst E.

Med Decis Making. 2007 Nov-Dec;27(6):789-821. Review.

PMID:
18057191
13.

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, de Smedt G, Baeten B, Beets G, Sinha R, Woodfall B; DUET-2 study group.

Lancet. 2007 Jul 7;370(9581):39-48.

PMID:
17617271
14.

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, Pialoux G, Wilkin T, Peeters M, Vingerhoets J, de Smedt G, Leopold L, Trefiglio R, Woodfall B; DUET-1 study group.

Lancet. 2007 Jul 7;370(9581):29-38.

PMID:
17617270
15.

Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.

Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, Mens H, Clumeck N, Viksna L, Antunes F, Machala L, Lundgren JD; EuroSIDA Study Group.

AIDS. 2007 Mar 30;21(6):721-32.

PMID:
17413693
16.

Drug resistance after failure of initial antiretroviral therapy in resource-limited countries.

Gallant JE.

Clin Infect Dis. 2007 Feb 1;44(3):453-5. Epub 2006 Dec 27. No abstract available.

17.

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.

Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W.

Clin Infect Dis. 2007 Feb 1;44(3):447-52. Epub 2006 Dec 27.

18.

HIV viral load monitoring in resource-limited regions: optional or necessary?

Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, Goemaere E, Garcia de la Vega F, Perrin L, Rodriguez W.

Clin Infect Dis. 2007 Jan 1;44(1):128-34. Epub 2006 Nov 28.

19.

Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure.

Goetz MB, Ferguson MR, Han X, McMillan G, St Clair M, Pappa KA, McClernon DR, O'Brien WA.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):541-9.

20.

Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings.

Moore DM, Mermin J, Awor A, Yip B, Hogg RS, Montaner JS.

J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):436-9.

PMID:
17019367
Items per page

Supplemental Content

Write to the Help Desk